Study Design and patient selection
nausea, vomiting
ONCOLOGY, SOLID TUMOR
Patients were included if their age were 18 years or older with a diagnosis of solid tumor receiving HEC regimen, which includes platinum or anthracycline-based chemotherapy. Patients received carboplatin AUC 5 mg/ml/min i.v. on days 1, cisplatin 75 mg/m2 i.v. on days 1 or epirubicin 90 mg/m2 every 21 days. Patients' Eastern Oncology Collaboration (ECOG) physical status score 0–2 (including boundary values). The regimens were classified as HEC based on NCCN, ESMO and CSCO guidelines [Patients were randomly assigned to either fosaprepitant 150 mg on day 1 (regular group) or 150 mg once per day on days 1 and 3 (prolonged group). Palonosetron 0.25 mg was administered once per day on days 1. Dexamethasone 6 mg on day 1 and 4 mg once per day on days 2 and 3 was used as baseline antiemetic prophylaxis. Detailed study designs are summarized in Supplementary Fig. The primary endpoint were incidence of delayed nausea and delayed vomiting. The second endpoint was related AEs. All the endpoints above were defined according to CTCAE 5.0.